Serum prostate specific antigen (ELSA-PSAR monoclonal immunoradiometric assay) was determined in 43 patients with untreated prostatic adenocarcinoma as well as 36 patients with BPH. And serum prostatic acid phosphatase (Gamma DabR
radioimmunoassay) was
also measured to investigate the value as another tumor marker. Mean values of serum PSA in normal controls, patients with BPH and patients with prostatic adenocarcinoma were 2.09±0.16ng/ml, 11.31±2.24ng/ml and 666±109ng/ml, respectively
(P<0.01). Of
36 patients with BPH, 22(61%) patients showed increased values of serum PSA were increased significantly as advancement of clinical cancer stage, and statistically significant differences were noticed in PSA values between 2 groups of patients
with
low
(Gleason sum≤6) and high Gleason sum≥7) (P<0.01).
Marked decreases of serum PSA levels were observed in short intervals after orchiectomy in stage D prostate cancer(41% and 78% decrease of preoperative levels at I week and 1 month, respoctively). Serum PSA levels were relatively coincident with
the
clinical status of the patients, and decreased to the normal range within 4 months with improvement of symptoms in 5 of 12 patients followed (from 2 to 15 months with a mean of 8 months) after anti-androgen therapy, and the average rate of
decrease of
PSA levels was 185ng/ml/month.
We concluded that PSA is a sensitive serum tumor marker for glandular differentiation, staging and monitoring the response after treatment in prostatic adenocarcinoma.
|